GCFLU Quadrivalent (GC Biopharma Corp)

GCFLU Quadrivalent is a quadrivalent, inactivated, egg-derived, split-virion influenza vaccine developed by GC Pharma (formerly Green Cross Corporation). It contains 15 µg of hemagglutinin (HA) antigen from each of four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Yamagata and Victoria), for a total of 60 µg per 0.5 mL dose. The vaccine works by inducing the immune system to produce antibodies against the viral hemagglutinin protein, thereby preventing the virus from attaching to and infecting host cells. Approved by South Korea's Ministry of Food and Drug Safety in 2015 for adults and in 2018 for children as young as 6 months, it is used for the prevention of seasonal influenza. A newer formulation, GC3110B, has been evaluated in Phase 3 clinical trials to confirm its safety and immunogenicity compared to the original formulation.

Brand names

GCFLU Quadrivalent

Other names

Green Cross Quadrivalent Influenza Vaccine